bankruptcy

The company had previously declared Chapter 11 bankruptcy, which would have enabled it to reorganize to stay afloat and pay its creditors over time.

The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.

Rosetta had disclosed that it intended to file for bankruptcy after its merger with Genoptix was not completed as planned.

The company is developing tests based on the analysis of the spatial patterns of chromosomes by tagging and imaging their telomeres.

Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests. 

The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."

Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.